Ovid Therapeutics Inc.

Ovid Therapeutics Inc.

OVID · Nasdaq

Ovid Therapeutics Inc. (OVID) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Ovid Therapeutics Inc. in 2026. The next earnings report is expected on November 11, 2026.

Earnings calendar

Next earnings date

11 Nov 2026

In 82 days

EPS estimate

-0.10

Revenue estimate

22.8K

Past earnings

13 Aug 2026
EPS actual
-0.08 (+30.4%)
estimate -0.12
Revenue actual
733.0K (+3,320.6%)
estimate 21.4K
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
12 May 2026
EPS actual
-0.12 (+2.9%)
estimate -0.12
Revenue actual
0 (-100.0%)
estimate 56.7K
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
18 Mar 2026
EPS actual
0.06 (+151.2%)
estimate -0.12
Revenue actual
718.0K (+817.6%)
estimate 78.3K
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
12 Nov 2025
EPS actual
-0.17 (-13.4%)
estimate -0.15
Revenue actual
132.0K (-32.2%)
estimate 194.7K
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Ovid Therapeutics Inc. beat consensus estimates in its latest earnings report, with EPS of $-0.08 versus an estimate of $-0.115 and revenue of $733 thousand versus an estimate of $21.43 thousand, 3320.6% above expectations. In the prior quarter EPS also came in ahead of expectations while revenue missed estimates.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
Margaret Alexander
Employees
23
IPO date
05 May 2017
ISIN
US6904691010
Website
ovidrx.com

Frequently asked questions

When does Ovid Therapeutics Inc. (OVID) next report earnings?

Ovid Therapeutics Inc. (OVID) is scheduled to report earnings on November 11, 2026.

What was Ovid Therapeutics Inc.'s most recent earnings date?

Ovid Therapeutics Inc. (OVID) last reported earnings on August 13, 2026.

Where is Ovid Therapeutics Inc. stock listed?

Ovid Therapeutics Inc. (OVID) is listed on Nasdaq.